Advances in Medical Management of Overactive Bladder

Richelson, Elliott; Elliott, Daniel S.
June 2003
Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p681
Academic Journal
Editorial. Discusses advances in the medical management of overactive bladder or urinary incontinence. Oral extended-release forms of two different muscarinic receptor antagonists, oxybutynin and tolterodine; Introduction of the transdermal oxybutynin patch; Pharmacokinetic difference between transdermal and oral preparations.


Related Articles

  • Prospective Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial. Diokno, Ananias C.; Appell, Rodney A.; Sand, Peter K.; Dmochowski, Roger R.; Gburek, Bernard M.; Klimberg, Ira W.; Kell, Sherron H. // Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p687 

    • Objective: To compare the efficacy and tolerability of extended-release formulations of oxybutynin chloride and tolterodine tartrate in women with overactive bladder. • Patients and Methods: The OPERA (Overactive bladder: Performance of Extended Release Agents) trial was a...

  • Pharmacokinetics and Metabolism of the Novel Muscarinic Receptor Agonist SNI-2011 in Rats and Dogs. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; Masunaga, Hiroaki // Drug Research / Arzneimittel-Forschung;Jan2003, Vol. 53 Issue 1, p26 

    In this study, the pharmacokinetics of SNI-2011 ((�)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]monohydro chloride hemihydrate, cevimeline, CAS 153504-70-2), a novel muscarinic acetylcholine receptor agonist developed for the treatment of Sj�gren's syndrome, in rats and dogs...

  • Which oral therapy warranted in urge urinary incontinence?  // PharmacoEconomics & Outcomes News;1/15/2005, Issue 469, p12 

    Presents information on the different oral therapies for treating urge urinary incontinence. Types of oral medication evaluated; Problems found in several of the treatments; Comparison between the annual costs of the therapies.

  • Clinical pharmacokinetics of drugs used to treat urge incontinence. Guay, David R.P. // Clinical Pharmacokinetics;Nov2003, Vol. 42 Issue 14, p1243 

    Urge incontinence (also known as overactive bladder) is a common form of urinary incontinence, occurring alone or as a component of mixed urinary incontinence, frequently together with stress incontinence. Because of the pathophysiology of urge incontinence, anticholinergic/antispasmodic agents...

  • A benefit-risk assessment of extended-release oxybutynin. Michel, M.C.; Michel, Martin C // Drug Safety;Sep2002, Vol. 25 Issue 12, p867 

    Oxybutynin is a muscarinic receptor antagonist, which has been available for a number of years in its original immediate-release (IR) formulation. While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly...

  • Long-term effects of injections of collagen into the urethral submucosa for the treatment of incontinence in bitches.  // Veterinary Record: Journal of the British Veterinary Association;4/2/2005, Vol. 156 Issue 14, p437 

    Examines the long-term effects of injections of collagen into the urethral submucosa for the treatment of incontinence in bitches. Duration of the follow up on bitches; Improvement seen in dogs which had received additional treatment with alpha-adrenergic agonists; Development of mild,...

  • Oxybutynin Topical.  // AHFS Consumer Medication Information;Apr2018, p1 

    Oxybutynin topical gel is used to control frequent urination, urgent need to urinate, and urge urinary incontinence (sudden strong need to urinate that may cause urine leakage) in people who have overactive bladder (OAB; condition in which the bladder muscles tighten uncontrollably to empty the...

  • Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin. Doroshyenko, Oxana; Fuhr, Uwe // Clinical Pharmacokinetics;2009, Vol. 48 Issue 5, p281 

    The succinate salt of solifenacin, a tertiary amine with anticholinergic properties, is used for symptomatic treatment of overactive bladder. Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10mg solifenacin dose,...

  • Phenylpropanolamine toxicosis in dogs and cats. Holding, Judy K. // Veterinary Medicine;Jan2012, Vol. 107 Issue 1, p18 

    The article focuses on the pharmacokinetics, mechanism of action, toxicology, and the use of phenylpropanolamine (PPA) in veterinary medicine in the U.S. It notes that PPA is used in treating urinary incontinence secondary to urethral sphincter hypotonia in dogs and cats. This drug is readily...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics